Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25291676 | 0.86 | RORC (0.39) | RORCCCR5 | |
| SCHEMBL30496260 | 0.80 | GPR119 (0.51) | KCNH2 | |
| SCHEMBL25283318 | 0.80 | GPR119 (0.51) | KCNH2 | |
| SCHEMBL25423554 | 0.80 | CCR5 (0.43) | RORCCCR5 | |
| SCHEMBL30478166 | 0.75 | RXFP1 (0.43) | PIM1HSP90AA1HRH4SCN7AKCNH2 | |
| SCHEMBL25297679 | 0.75 | ALDH1A1 (0.42) | — | |
| SCHEMBL30496194 | 0.69 | EGLN1 (0.45) | HSP90AA1SCN7AKCNH2SCN9ARXFP1 | |
| SCHEMBL4503101 | 0.69 | HRH4 (0.46) | HSP90AA1HRH4RXFP1PTGS2 | |
| SCHEMBL5417056 | 0.69 | RXFP1 (0.54) | HSP90AA1HRH4RXFP1 | |
| SCHEMBL30496247 | 0.69 | GPR119 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | PIM1 2270/4885HSP90AA1 2316/4885HRH4 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.